Whereas J&J has stored its Ottava robotic beneath wraps, it stated the system presents surgical groups the flexibility to adapt to medical workflows and particular person affected person wants. | Supply: Johnson & Johnson
Johnson & Johnson MedTech this week introduced that it has accomplished the primary circumstances within the medical trial for its OTTAVA Robotic Surgical System. The circumstances mark the primary medical expertise with the OTTAVA System, it stated.
“We’re proud to achieve this essential milestone in our robotic surgical procedure program,” stated Hani Abouhalka, the corporate group chairman of surgical procedure at Johnson & Johnson MedTech.
“OTTAVA is a key innovation in our portfolio of superior surgical applied sciences – all of that are designed to rework the surgical experiences throughout all surgical procedure,” he added. “Our folks work side-by-side with surgical groups in ORs [operating rooms] world wide every single day to boost the usual of take care of sufferers and ship what’s subsequent in surgical procedure.”
Johnson & Johnson MedTech is a unit of New Brunswick, N.J.-based Johnson & Johnson (J&J), which has greater than 100 years of expertise in drugs and surgical know-how. The corporate stated its portfolio contains robotics, wound closure, adjunctive hemostats, surgical stapling and devices, and digital programs.
OTTAVA addresses surgical robotics shortcomings
The U.S. Meals and Drug Administration (FDA) granted OTTAVA an investigational machine exemption in late 2024. Johnson & Johnson MedTech stated it designed the system to advance medical innovation usually surgical procedure, a big a part of its broader surgical procedure enterprise.
J&J described OTTAVA as “a multi-specialty soft-tissue surgical procedure robotic, supporting a broad vary of procedures throughout affected person anatomy and surgical specialties, together with probably the most complicated surgical procedures that require a multi-quadrant method.” The system’s unified structure, surgical instrumentation constructed on J&J’s Ethicon expertise, and a deliberate connection to the Polyphonic digital ecosystem are supposed to fulfill the wants of every affected person’s care and every surgeon’s medical method, the corporate asserted.
Johnson & Johnson MedTech first shared particulars about OTTAVA about 4 years in the past. Since then, it has been comparatively quiet. In October 2021, the corporate pushed again the platform’s improvement timeline by about two years, citing a number of elements.
OTTAVA’s preliminary design included six robotic arms. In November 2023, a J&J replace included modifications, together with 4 arms to be obtainable on demand.
Register now so you do not miss out!
Johnson & Johnson MedTech preps for subsequent steps
Dr. Erik Wilson is the chief of minimally invasive and elective common surgical procedure on the College of Texas Well being Houston and the lead investigator for the medical research. He carried out a Roux-en-Y gastric-bypass surgical procedure utilizing the OTTAVA Robotic Surgical System at Memorial Hermann-Texas Medical Middle.
“Surgical robotics is on the forefront of innovation in minimally invasive surgical procedure,” stated Wilson. “I’m proud to have carried out the primary medical research circumstances with OTTAVA and doubtlessly assist advance the usual in surgical robotics.”
Johnson & Johnson MedTech plans to make use of knowledge from this trial goals to help the surgical system’s capability to carry out a wide range of procedures. Upon completion of the research, the corporate plans to submit the OTTAVA system for De Novo authorization within the U.S.
J&J stated it would goal a sign protecting a number of procedures usually surgical procedure throughout the higher stomach. These embody gastric bypass, gastric sleeve, small bowel resection, and hiatal hernia restore.
“As an organization working on the intersection of biology and know-how, medical proof era is the core of our innovation applications to advance surgical know-how for sufferers,” stated Peter Schulam M.D., Ph.D., and chief scientific officer at Johnson & Johnson MedTech. “By way of this medical research, we’re proud to be partnering with surgeons to collect proof and help the continuing pursuit of scientific research for the development of robotic-assisted minimally invasive surgical procedure.”
The OTTAVA robotic system is beneath improvement and isn’t but licensed to be marketed or offered in any market, famous J&J.
